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Objective: We sought to establish the outcome and optimal therapeutic
sequence for patients with nonmetastatic Ewing sarcoma/primitive neuroec-
todermal tumor of the chest wall.
Methods: Patients 30 years of age or younger with nonmetastatic Ewing sar-
coma/primitive neuroectodermal tumor of the bone were randomly assigned
to receive vincristine, doxorubicin, cyclophosphamide, and dactinomycin or
those drugs alternating with ifosfamide and etoposide. Local control was
obtained with an operation, radiotherapy, or both.
Results: Fifty-three (13.4%) of 393 patients had primary tumors of the chest
wall (all rib). Event-free survival at 5 years was 57% for the chest wall com-
pared with 61% for other sites (P > .2). Ifosfamide and etoposide improved
outcome in the overall group (5-year event-free survival, 68% vs 54%; P =
.002), and a similar trend occurred in chest wall lesions (5-year event-free
survival, 64% vs 51%). Patients with chest wall lesions had more attempts at
initial surgical resection (30%) than those with other primary tumor sites
(8%, P < .01). The attempt at initial resection for chest wall lesions did not
correlate with size. Initial resections at other sites were restricted to smaller
tumors. Initial resection resulted in negative pathologic margins in 6 of 16
patients, whereas the delayed resection resulted in negative margins in 17 of
24 patients (P = .05). Although there was no difference in survival by timing
of the operation in rib lesions, a higher percentage of patients with initial sur-
gical resection received radiation than those with resection after initial
chemotherapy (P = .13).
Conclusions: Although rib primary tumors are significantly larger than
tumors found in other sites, their outcome is similar. We favor delayed resec-
tion whenever possible to minimize the number of patients requiring radia-
tion therapy. (J Thorac Cardiovasc Surg 2000;119:1154-61)
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E wing sarcoma is the most frequent chest wall tumoroccurring in children and adolescents. It is an
extremely aggressive tumor, and management requires
intensive local therapy with surgical resection, radio-
therapy, or both, as well as adjuvant chemotherapy to
prevent or treat metastases. Local recurrence in this
tumor has been frequent. An intergroup study with two
new agents in the treatment of this tumor recently has
been completed. We have reviewed the patients in this
study with chest wall tumors because particular con-
sideration is required for treatment of this location.
Radiation administered to the chest is less well tolerat-
ed than that administered to other sites because of
exposure to the heart and lungs. Also, the ribs have
often been considered as expendable bones in contrast
to the central axial skeleton and certain long bones of
the extremities.
Methods
Patients and therapeutic plan. Intergroup study INT-
0091 (CCG 7881, POG 8850) was opened to all member
institutions of the Children’s Cancer Group and the
Pediatric Oncology Group in December 1988 and closed in
November 1992. Patients accrued to this study were 30
years of age or less at diagnosis, with a primary bone tumor
that had a histologic diagnosis of Ewing sarcoma, periph-
eral neuroectodermal tumor, or primitive sarcoma of bone.
Prior anticancer therapy other than an operation to obtain a
diagnosis was not allowed. To retain eligibility, protocol
chemotherapy had to start within 1 month of the diagnostic
biopsy. Patients, guardians, or both had to give informed
written consent according to institutional guidelines to par-
ticipate.
Patients were randomized at study entry to receive standard
chemotherapy with doxorubicin, vincristine, cyclophos-
phamide, and dactinomycin or to receive the experimental
therapy consisting of those 4 drugs alternating with courses
of ifosfamide and etoposide. Randomization was stratified
into groups according to the presence of metastases. Details
of the chemotherapy regimens are presented elsewhere.1 This
report is restricted to patients without metastatic disease at
diagnosis.
Local control measures consisted of either radiation thera-
py, an operation, or both. The protocol called for delivery of
local control at 12 weeks. The treating physicians decided
which local control modality to use in each case, and this fac-
tor was not a randomized variable; the protocol allowed an
operation for tumors deemed to be resectable. For patients
receiving radiotherapy alone, the initial tumor volume (soft
tissue and osseous extent of tumor) with a 3-cm margin was
treated to 4500 cGy. This was followed by a reduction in
treatment volume to the postchemotherapy, preradiotherapy
extent of tumor for an additional 1080 cGy, resulting in a total
dose of 5580 cGy. Patients with residual tumor after an oper-
ation also were irradiated after these dose-volume guidelines
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for gross residual disease and 4500 cGy with a 1-cm margin
for microscopic disease. The protocol allowed for attempted
surgical resection before the start of chemotherapy and after
consultation with the study chair and surgical members of the
study committee.
Estimation of size of tumor at diagnosis. The 3 largest
perpendicular measures of the patient’s primary tumor, as
determined by computed tomography, were to be supplied at
the time of study entry. For patients for whom all 3 measure-
ments were reported, tumor volume was estimated by the
product of the 3 perpendicular measures. If one or more of
the measurements were not available, the tumor volume was
not estimated.
Statistical analysis. Adverse event-free survival (EFS)
was defined to be the time from study entry until disease pro-
gression, diagnosis of a second malignant neoplasm, death, or
last patient contact when an event was considered to have
occurred, whichever came first. Otherwise, the patient was
censored at the date of last contact. Data current to December
1997 were used in the analysis.
For a patient to be considered capable for evaluation for
local control, the individual must have started maintenance
after all local interventions were completed. Adverse EFS
after local control was defined to be the time from the start of
maintenance therapy until disease progression, diagnosis of a
second malignant neoplasm, death, or last patient contact,
whichever came first. If the patient experienced disease pro-
gression, diagnosis of a second malignant neoplasm or death
after an event was considered to have occurred. Otherwise,
the patient was censored at the date of last contact.
The survivor functions for EFS and EFS after local control
were estimated by the method of Kaplan and Meier.2 Risk for
adverse event was compared across groups defined by treat-
ment or prognostic factors by the log-rank statistic.2 The
patient’s randomized treatment assignment was used in all
comparisons involving regimen. Hazard ratios (HRs) and
associated confidence intervals (CIs) were estimated by the
proportional hazards regression model.2
The proportional hazards regression model was used to
determine, for patients with rib primary tumors, which fac-
tors were independently prognostic for outcome. All factors
that were significant at the .10 level in univariate analyses, as
well as the randomized regimen, were selected for inclusion
in a backward stepwise model. Age and tumor volume were
selected by this screening process. The absolute value of age
and tumor volume were used. Modifying these effects with
quadratic terms did not significantly improve fit. A multi-
plicative interaction term for age and tumor volume was
included in the regression model used to start the backward
stepwise procedure. Terms that were significant at the .05
level or less in the final model were considered independent-
ly prognostic for risk of adverse events.
Qualitative characteristics were compared across sub-
groups by means of the exact conditional test of proportions.3
In particular, tumor size was classified as above or below
median and compared across groups defined by site of pri-
mary tumor.
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Results
Three hundred ninety-three eligible patients with
nonmetastatic Ewing sarcoma were entered on the
study. Fifty-three patients had a primary tumor located
in the ribs, and 340 had primary tumors located at other
sites. There were no sternal primary tumors.
Two hundred twenty-six patients had sufficient data
submitted to estimate tumor volume. Patients without
tumor volume calculated were distributed similarly
across the various primary tumor sites when compared
with patients with known volumes. Rib lesions were sig-
nificantly larger than tumors at some other sites and most
closely resembled pelvic tumors in volume (Table I).
Two patients did not have any data submitted to
describe the surgical procedures performed as part of
protocol therapy. These individuals are excluded from
subsequent analyses.
Sixteen patients with rib primary tumors had an
attempt to resect the tumor before the start of
chemotherapy. Patients with rib primary tumors were
significantly more likely to have initial surgical exci-
sion attempted when compared with patients with
tumors of other sites (30% vs 8%, P < .01). Attempts at
initial resection for chest wall lesions were not associ-
ated with size of tumor, as assessed by largest diameter
in contrast to tumors at other sites, where initial resec-
tions were done only rarely in large tumors (Table II).
Data from the local pathologist were available for 16
of the initial resections. Sixty-two percent (10/16) were
determined to have tumor at the margin of resection.
Data from the local pathologist was available for 24 of
the 30 patients who underwent an operation after
induction therapy. Tumor was found at the margin of
resection in 7 (29%) of these patients (P = .05).
The type of local therapy delivered after induction as
it relates to initial local therapy is demonstrated in
Table III. Patients who had an initial resection were
more likely to receive radiation therapy than those who
had resections after initial chemotherapy, although this
was not significant at the .05 level (P = .13).
The 5-year EFS for all 393 patients with nonmetasta-
tic disease was 61% (95% CI, 55%-66%; Fig 1). EFS
at 5 years was 57% for the chest wall compared with
61% at all other sites (HR for chest wall tumor, 0.88;
95% CI, 0.56-1.4; P = .6). Ifosfamide and etoposide
significantly improved outcome in the overall group
(5-year EFS, 68% vs 54% for standard chemotherapy;
HR, 0.61; 95% CI, 0.44-0.84; P = .002); the same
trend was seen for chest wall lesions but did not reach
statistical significance (5-year EFS, 64% vs 51% for
standard chemotherapy; HR, 0.61; 95% CI, 0.27-1.4;
P = .2). The site of the primary tumor was associated
with risk for adverse event. Patients with rib primary
tumors had outcomes comparable with those of
patients with primary tumors in the femur or humerus
and outcomes superior to those of patients with pelvic
primary tumors (Fig 2; HR for femur or humerus pri-
mary tumor, 0.84; HR for pelvic primary tumor, 1.3;
HR for any other site, 0.69; P = .03). Patients with rib
lesions of volume greater than the median for this site
were at increased risk for an adverse event (Fig 3; HR,
3.3; 95% CI, 1.0-11), as were older patients (Fig 4; HR
for patients 10-17 years of age, 2.4; HR for patients 18
years or older, 7.8; P = .03). Risk for an adverse event
was not related to an initial attempt at resection (Fig 5;
HR, 0.72; 95% CI, 0.28-1.8; P = .5). The type of local
Table I.  Size of primary tumors by site (calculated
volume)
Site of primary tumor
Tumor Humerus,
volume Rib Pelvis femur, or both Other
<240 cm3 11 (32%) 17 (31%) 25 (43%) 55 (69%)
≥240 cm3 23 (68%) 37 (69%) 33 (57%) 25 (31%)
Rib and pelvic tumors are similar in size, and both are significantly larger than
tumors at sites other than the pelvis or ribs (P < .001). Values in parentheses
represent the percentage of patients with primary tumors at a particular loca-
tion for each volume category.
Table II. Relationship of primary tumor site and size
by largest tumor dimension to likelihood of initial
attempt at resection
Primary site <8 cm ≥8 cm
Ribs 5/14* (36%) 9/33 (27%)
Other 18/102 (18%) 4/173 (2%)
Size did not correlate with initial attempt at resection for rib primary tumors
(P = .9) in contrast to other sites, where initial resection was attempted sig-
nificantly less often in tumors with a maximum dimension of 8 cm or larger
(P < .001).
*The first entry represents the number of patients for whom a resection was
attempted. The second entry is the total number of patients in the tumor
dimension category.
Table III. Final local control method segregated 
by initial surgical intervention
Operation as the only Local control included 
local method used radiation therapy
Initial attempt 4* 11
at resection
Initial biopsy 17 17†
The P value for independence of the chance of receiving radiation therapy as
part of local control and initial attempted complete resection was .13.
*Includes 1 patient who had a second resection after induction chemotherapy.
†Includes 5 patients who had radiation therapy only as the local control
method.
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control measures also was not related to EFS after local
control (Fig 6; HR for operation, 0.35; HR for opera-
tion plus radiation therapy, 0.48; P = .3).
The backward stepwise model demonstrated that
both increased tumor volume and increased age were
factors independently associated with elevated risk for
adverse events in patients with rib primary tumors.
There was no evidence of an interaction between the
two factors.
Complete data regarding the surgical resection was
available on 34 patients. The magnitude of chest wall
resection is shown in Table IV. Prosthetic mesh was
Fig 1.  Kaplan-Meier estimate of EFS for all patients with nonmetastatic disease at study entry (n = 393).
Fig 2.  Kaplan-Meier estimates of EFS for patients with nonmetastatic disease at study entry according to site of
primary tumor (P = .03): ribs (n = 53), humerus or femur (n = 100), pelvis (n = 93), or other site (n = 147).
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used for reconstruction in 19 children (polytetrafluo-
roethylene,* 9 children; Marlex mesh [Bard Implants,
Billerica, Mass], 6 children; Prolene mesh [Ethicon,
Inc, Somerville, NJ], 2 children; Vicryl mesh [Ethicon],
2 children; and dural graft, 1 child). In 1 child a pros-
thetic sandwich reconstruction was performed, and in
another child a frozen rib allograft was placed. A lung
was adherent to the mass in 18 patients, and a wedge
resection was performed in 15 patients. Adherent
diaphragm was resected in 9 patients, and in all cases
primary closure was possible. Muscle flap rotation was
Fig 3.  Kaplan-Meier estimates of EFS for patients with nonmetastatic rib primary tumors according to estimated
tumor volume (P = .03): 419 cm3 or less or greater than 420 cm3.
Fig 4.  Kaplan-Meier estimates of EFS for patients with nonmetastatic rib primary tumors according to age at study
entry (P = .01): 10 years or younger (n = 19), 10 to 17 years (n = 30), or older than 17 years (n = 4).
*Gore-Tex mesh, registered trademark of W. L. Gore & Associates,
Inc, Flagstaff, Ariz)
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performed in 4 patients (pectoral muscle, 1 patient;
latissimus dorsi muscle, 3 patients).
Few complications were reported. Only 2 were
reported in the 16 attempted resections before
chemotherapy. Both patients had intraoperative hemor-
rhage. There was 1 incident of intraoperative hemor-
rhage and 1 incident of delayed wound healing among
the resections attempted after induction chemotherapy.
Discussion
In this large study of primitive neuroectodermal
tumor and Ewing sarcoma of bone, rib primary tumors
did as well or better than primary tumors of similar size
at other sites. As in other sites, outcome correlated with
size and age, as well as whether the patient received the
experimental therapy, although the latter did not reach
statistical significance for the rib lesions. Surgeons are
more likely to attempt an initial resection for patients
with rib primary tumors. In contrast to other sites, ini-
tial resection of the ribs was attempted, even with very
large primary tumors.
Should one attempt initial resection in Ewing sarco-
ma/primitive neuroectodermal tumor of the ribs? We
found no difference in eventual outcome for patients
who had initial resection compared with those who had
initial biopsy only, but the numbers are limited in this
study. Importantly, however, more patients with an ini-
tial attempt at resection required eventual radiation
therapy than those patients who had their resection
after initial shrinkage of the tumor with chemotherapy.
Radiation therapy has special side effects in the chest,
where large volumes of lung may be damaged with the
required high doses of radiation therapy.4 In addition,
the heart may be in the field, and radiation to the heart
is believed to add toxicity to the damage caused by an
essential chemotherapeutic agent for this disease, dox-
orubicin.5,6 Finally, the risk of second malignant neo-
plasms after radiation therapy in Ewing sarcoma is
quite high (10%-30%).7-9
We therefore agree with Rao and others, who believe
that initial attempts at resection should rarely be done in
Ewing sarcoma/primitive neuroectodermal tumor of the
chest wall.10-12 After initial chemotherapy, the tumors are
generally smaller and the margins of involvement are bet-
ter defined, resulting in an increased proportion of resec-
tions with negative microscopic margins, as was found in
this study. A limited number of children will require radi-
Fig 5.  Kaplan-Meier estimates of EFS for patients with nonmetastatic rib primary tumors according to whether the
operation was conducted before the start of systemic chemotherapy (P = .5): yes (n = 16) versus no (n = 35).
Table IV.  Definitive chest wall resections
No. of No. of Patients with Patients with
ribs resected patients prosthetic graft muscle flap
1 8 2 1
2 9 5
3 18 8 1
4 6 5 2
Total 41 20 4
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ation therapy because of paravertebral involvement, size
of the lesion, apical location of the tumor, or incomplete
resection of the tumor at a delayed operation. EFS for
patients without metastases now is nearly 60%, regard-
less of the form of local treatment. Any therapy that
might lead to long-term side effects, such as radiation,
should be avoided if possible, and this can best be
achieved by use of initial chemotherapy before attempted
resection.
We thank the investigators of the Pediatric Oncology
Group and the Children’s Cancer Group and the many pathol-
ogists, surgeons, pediatricians, radiation oncologists, and
other health professionals who managed the children entered
into this study.
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